Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1 week of infusion in patients with congestive heart failure

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 4, 2005, Pages 513-518

  Ishikawa, Chitose ^a   Tsutamoto, Takayoshi ^a   Wada, Atsuyuki ^a   Fujii, Masanori ^a   Ohno, Keijin ^a   Sakai, Hiroshi ^a   Yamamoto, Takashi ^a   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Aldosterone; Atrial natriuretic peptide; Congestive heart failure; Endothelin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR ALPHA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC GMP; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENDOTHELIN 1; GUANYLATE CYCLASE; INOTROPIC AGENT; LOOP DIURETIC AGENT; MILRINONE; NEUROHORMONE; RECEPTOR; SPIRONOLACTONE;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; SYMPTOMATOLOGY;

ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CARDIOMYOPATHY, DILATED; CHRONIC DISEASE; CYCLIC GMP; ENDOTHELIN-1; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME;

EID: 26044446424     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000177980.83810.2e     Document Type: Article

References (28)

1. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
2. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation. 1988;77:721-729.
3. Remes J, Tikkanen I, Fyhrquist F, et al. Neuroendocrine activity in untreated heart failure. Br Heart J. 1991;65:249-255.
4. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med. 1991;114:464-469.
5. Cody RJ, Hass GJ, Binkley PF, et al. Plasma endothelin correlates with extent of pulmonary hypertension in patients with chronic heart failure. Circulation. 1994;85:504-509.
6. Tsutamoto T, Wada A, Maeda Y, et al. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 1994;23:1427-1433.
7. Tsutamoto T, Hisanaga T, Fukai D, et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol. 1995;76:803-808.
8. Pacher R, Stanek B, Hulsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27:633-641.
9. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730-1736.
10. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-516.
11. Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;135:825-832.
12. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1587-1593.
13. Scriven TA, Burnett JC Jr. Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure. Circulation. 1985;72:892-897.
14. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal, hormonal, and hemodynamic responses peptide infusion. J Clin Invest. 1986;78:1362-1374.
15. Brans MW, Freeman RH. Aldosterone and renin inhibition by physiological levels of atrial natriuretic factor. Am J Physiol. 1988;254: R1011-R1016.
16. Wada A, Tsutamoto T, Matsuda Y, et al. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation. 1994;89:2232-2240.
17. Saito Y, Nakao K, Nishimura K, et al. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation. 1987;76:115-124.
18. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581-1588.
19. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37-44.
20. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2001;37:820-826.
21. Tsutamoto T, Kanamori T, Morigami N, et al. Possibility of down-regulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation. 1993;87:70-75.
22. Elkayam U, Akhter MW, Singh H, et al. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol. 2003;93:237-240.
23. Silver MA, Horton DP, Ghali JK, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39:798-803.
24. Burger AJ, Aronson D, Horton DP, et al. Comparison of the effects of dobutamine and nesititide on ventricular ectopy in acutely decompensated ischemic versus nonischemic cardiomyopathy. Am J Cardiol. 2003;91:1370-1372.
25. Burger AJ, Horton DP, LeJemtel T, et al. Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Natrecor Therapy. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. 2002;144:1102-1108.
26. Wada A, Tsutamoto T, Maeda Y, et al. Endogenous atrial natriuretic peptide inhibits endothelin-1 secretion in dogs with severe congestive heart failure. Am J Physiol. 1996;270:H1819-H1824.
27. Aronson D, Burger AJ. Intravenous nesiritide reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol. 2002;90:435-438.
28. Aronson D, Burger AJ. Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: role of endothelin. Pacing Clin Electrophysiol. 2003;26:703-710.